Other
Immunoglobulin G4-Related Disease
0
Pipeline Programs↗
0
Active Trials↗
0
Companies Involved↗
Immunoglobulin G4-related Disease is an early-stage landscape with 0 programs across 0 companies.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
1
clinical trials
Terminated1 · 100%
Clinical Trials
Trial Activity
Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD)
Terminated·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT04918147·8 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)